Retrovirus-mediated gene transfer

Biologic

Retrovirus-mediated gene transfer is one of 7 biologic programs targeting Wiskott-Aldrich syndrome. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Wiskott-Aldrich SyndromeActive, not recruiting

Wiskott-Aldrich SyndromePhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Wiskott-Aldrich Syndrome

#DrugCompanyPhaseTrials

Tepadina

Alnylam Pharmaceuticals

Alkeran

Busulfex

Nplate

2 5

Promacta

GSK

Phase 2

1 6

Interleukin 2

EEssen Biotech

Phase 1

1 7

Retrovirus-mediated gene transfer

DDavid Williams

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Wiskott-Aldrich syndrome1 trial

Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome

Completed·DDavid Williams·Phase 1/2·NCT01410825·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Retrovirus-mediated gene transfer. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Retrovirus-mediated gene transfer compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Retrovirus-mediated gene transfer. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — David Williams company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Company: DDavid Williams

Retrovirus-mediated gene transfer

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Wiskott-Aldrich syndrome1 trial

References

Drug Info

Quick Facts

Related News